[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100462699":3},{"organization":4,"armGroups":7,"interventions":27,"overallOfficials":53,"centralContacts":57,"locations":63,"responsibleParty":82,"collaborators":86,"id":93,"slug":94,"hasResults":95,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":99,"eligibilityCriteria":100,"healthyVolunteers":95,"sex":101,"minAge":102,"maxAge":85,"enrollmentInfo":103,"targetDuration":85,"studyType":106,"phases":107,"briefSummary":109,"conditions":110,"keywords":112,"overallStatus":66,"whyStopped":85,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":125},{"fullName":5,"class":6},"Sir Mortimer B. Davis - Jewish General Hospital","OTHER",[8,14,19,22],{"label":9,"type":10,"description":11,"interventionNames":12},"Sub-study 1 TNFi","ACTIVE_COMPARATOR","TNFi - any sub-cutaneous (sc) formulation, namely etanercept (receptor fusion protein), adalimumab (monoclonal antibody), golimumab (monoclonal antibody), or certolizumab (pegylated fragment of a monoclonal antibody)",[13],"Drug: TNFi",{"label":15,"type":10,"description":16,"interventionNames":17},"Sub-study 1 Anti-IL6","Anti-IL6 receptor monoclonal antibodies - tocilizumab or sarilumab",[18],"Drug: Anti-IL6",{"label":20,"type":10,"description":16,"interventionNames":21},"Sub-study 2 Anti-IL6",[18],{"label":23,"type":10,"description":24,"interventionNames":25},"Sub-study 2 JAKi","JAKi - tofacitinib (JAK1\u002F3 inhibitor), baricitinib (JAK 1\u002F2 inhibitor) or upadacitinib (JAK1 inhibitor)",[26],"Drug: JAKi",[28,38,45],{"type":29,"name":30,"description":31,"armGroupLabels":32,"otherNames":33},"DRUG","TNFi","TNFi - any sub-cutaneous (sc) formulation, namely etanercept (receptor fusion protein) 50 mg sc per week, adalimumab (monoclonal antibody) 40 mg sc every 2 weeks, golimumab (monoclonal antibody) 50 mg sc every month, or certolizumab (pegylated fragment of a monoclonal antibody) 400 mg sc at week 0, 2 and 4, and then 200 mg sc every 2 weeks or 400 mg sc every 4 weeks.",[9],[34,35,36,37],"Etanercept","Adalimumab","Golimumab","Certolizumab",{"type":29,"name":39,"description":40,"armGroupLabels":41,"otherNames":42},"Anti-IL6","Anti-IL6 receptor monoclonal antibodies - tocilizumab (if weight \\\u003C100 kg: 162 mg SC every other week, followed by an increase to weekly based on clinical response; if weight ≥100 kg: 162 mg SC weekly) or sarilumab (200 mg SC once every 2 weeks)",[15,20],[43,44],"Tocilizumab","Sarilumab",{"type":29,"name":46,"description":47,"armGroupLabels":48,"otherNames":49},"JAKi","JAKi - tofacitinib (JAK1\u002F3 inhibitor) 5 mg po bid, baricitinib 2 mg po qd (JAK 1\u002F2 inhibitor) or upadacitinib 15 mg po qd (JAK1 inhibitor)",[23],[50,51,52],"Tofacitinib","Upadacitinib","Baricitinib",[54],{"name":55,"affiliation":5,"role":56},"Marie Hudson, MD","PRINCIPAL_INVESTIGATOR",[58],{"name":55,"role":59,"phone":60,"phoneExt":61,"email":62},"CONTACT","514-340-8222","23476","marie.hudson@mcgill.ca",[64],{"facility":65,"status":66,"city":67,"state":68,"zip":69,"country":70,"countryCode":71,"cosmosGeoPoint":72,"geoPoint":77,"contacts":78},"Sir Mortimer B. Davis Jewish General Hospital","RECRUITING","Montreal","Quebec","H3T 1E2","Canada","CA",{"type":73,"coordinates":74},"Point",[75,76],-73.58781,45.50884,{"lat":76,"lon":75},[79],{"name":80,"role":59,"phone":81,"phoneExt":61,"email":62},"Marie Hudson, MD MPH","1-514-340-8222",{"type":83,"investigatorFullName":55,"investigatorTitle":84,"investigatorAffiliation":5,"oldNameTitle":85,"oldOrganization":85},"SPONSOR_INVESTIGATOR","Rheumatologist, Jewish General Hospital; Physician-scientist, Lady Davis Institute for Medical Research",null,[87,89,91],{"name":88,"class":6},"McGill University Health Centre\u002FResearch Institute of the McGill University Health Centre",{"name":90,"class":6},"Montreal General Hospital",{"name":92,"class":6},"Lady Davis Institute","100462699","stand-up-to-rheumatoid-arthritis-supra-100462699",false,"NCT05305066","Stand UP to Rheumatoid Arthritis (SUPRA)","Innovative Trial Designs, Multi-omics and Advanced Computational Prediction to Transform Clinical Care in RA","SUPRA","Inclusion Criteria:\n\n* Age ≥ 18 years;\n* Arthritis that fulfills the 2010 ACR\u002FEULAR classification criteria for RA;\n* Failure to standard conventional synthetic DMARDs and eligible for second-line b\u002FtsDMARDs (Sub-study 1) or failure to at least one TNF inhibitor and eligible for third-line b\u002FtsDMARDs (Sub-study 2).\n\nExclusion Criteria:\n\n* Prior b\u002FtsDMARDs for Sub-study 1 or prior b\u002FtsDMARDs other than TNF inhibitors for Sub-study 2;\n* Contraindication to b\u002FtsDMARD therapy, such as active infection or untreated latent TB, current malignancy, severe organ dysfunction, history of VTE (unless anticoagulated), high risk of cardiovascular disease, pregnancy\u002Flactation;\n* Overlap with another inflammatory disease requiring specific immunosuppressive therapy, such as lupus nephritis;\n* Unable to provide consent or complete forms (alone or with assistance) in English or French","ALL","18 Years",{"count":104,"type":105},75,"ESTIMATED","INTERVENTIONAL",[108],"NA","Rheumatoid arthritis is a disabling arthritis that affects young women disproportionately. Although the physicians have some excellent treatments, they do not know which treatment is best for which patient. The investigators want to find ways to identify the right drug for the right patient at the right time. This is what personalized medicine is all about.",[111],"Rheumatoid Arthritis",[113,114,115],"Rheumatoid arthritis","Pragmatic trials","Feasibility","2026-01-30",{"date":118,"type":119},"2026-02-03","ACTUAL",{"date":121,"type":119},"2023-02-01",{"date":123,"type":105},"2030-12",{"name":55,"class":6},1]